Ginkgo biloba / SMAD2 Cancer Research Results

Gb, Ginkgo biloba: Click to Expand ⟱
Features:
Ginkgo biloba from an ancient tree.
Ginkgo biloba leaf extracts (commonly standardized as EGb 761, ~24% flavonol glycosides and ~6% terpene lactones) are best known for antioxidant, anti-inflammatory, platelet-activating factor (PAF) antagonism, and neurovascular effects. In preclinical cancer models, Ginkgo constituents have been associated with modulation of NF-κB, Nrf2, MAPK, and PI3K/AKT pathways, along with effects on cell cycle, apoptosis, and angiogenesis. Clinical oncology evidence is limited and heterogeneous. Important safety considerations include antiplatelet effects (bleeding risk) and CYP/P-gp interactions (product- and dose-dependent).

-Ginkgo can inhibit platelet aggregation

-Scavenges free radicals; reduces oxidative stress in neuronal cells -Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-1β).
-Enhances microcirculation and oxygen delivery to brain tissues.
-Reduces Aβ plaque formation and associated neurotoxicity.
-May improve memory, attention, and processing speed in early-stage AD.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Antioxidant systems (Nrf2/ARE; SOD, GSH) Stress adaptation modulation (context-dependent) Nrf2 ↑; antioxidant enzymes ↑; oxidative injury ↓ R, G Redox buffering Flavonol glycosides commonly activate antioxidant defenses; direction in tumors is model-dependent.
2 NF-κB inflammatory transcription NF-κB ↓; cytokines/COX-2 ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory signaling Preclinical studies report NF-κB modulation; strength varies by constituent and dose.
3 PAF receptor antagonism (ginkgolides) Pro-tumor inflammatory signaling ↓ (context) Platelet activation ↓; microcirculation effects P, R Lipid mediator antagonism Ginkgolides are PAF antagonists; clinically relevant for antiplatelet/vascular effects.
4 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported; model-dependent) ↔ R, G Growth/survival modulation Observed in some tumor models; best described as reported/context-dependent.
5 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) ↔ P, R, G Stress/mitogenic signaling adjustment Directions vary by extract composition and cell type.
6 Cell-cycle control (Cyclins/CDKs) Cell-cycle arrest ↑ (reported) ↔ G Cytostasis Reported in vitro; typically downstream of signaling changes.
7 Intrinsic apoptosis (mitochondrial/caspase linked) Apoptosis ↑ (reported) ↔ G Cell death execution Seen in selected cancer cell lines; not a universal cytotoxin signature.
8 Angiogenesis signaling (VEGF & related) Angiogenic outputs ↓ (reported) ↔ G Anti-angiogenic phenotype Phenotype-level outcomes in some models; strength varies.
9 Drug metabolism / transport (CYPs, P-gp) Potential interaction with chemo agents (context) CYP/P-gp modulation (product- and dose-dependent) R, G Interaction constraint Reports of CYP (e.g., CYP2C19/3A4) and P-gp modulation are mixed; interaction risk depends on extract and dose.
10 Safety constraint (antiplatelet / bleeding risk) — Platelet aggregation ↓; bleeding risk ↑ (context) — Clinical risk management PAF antagonism and antiplatelet effects warrant caution with anticoagulants/antiplatelets and perioperatively.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor/mediator interactions; early redox shifts)
  • R: 30 min–3 hr (acute signaling and transcription changes)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
Ginkgo biloba — Alzheimer’s Disease (AD) Mechanism Table
Rank Pathway / Axis AD / Neural Context TSF Primary Effect Notes / Interpretation
1 Oxidative stress reduction (Nrf2/ARE; SOD, GSH) Oxidative injury ↓; lipid peroxidation ↓ R, G Neuroprotection via redox buffering Flavonol glycosides enhance endogenous antioxidant defenses and reduce oxidative stress, a core driver in AD pathology.
2 Mitochondrial protection ATP production stabilization; mitochondrial membrane integrity ↑ P, R Energy support EGb 761 has been reported to protect mitochondrial function and reduce ROS generation in neuronal models.
3 Neuroinflammation (NF-κB; microglial activation) Microglial activation ↓; pro-inflammatory cytokines ↓ R, G Anti-inflammatory neuroprotection Reduction of neuroinflammatory signaling may contribute to slowed neurodegenerative processes.
4 Platelet-activating factor (PAF) antagonism Improved cerebral microcirculation; reduced inflammatory mediator activity P Vascular support Ginkgolides act as PAF antagonists; improved cerebral blood flow may support cognition in vascular/mixed dementia.
5 β-amyloid aggregation modulation Aβ aggregation ↓ (reported in vitro) G Protein aggregation modulation Preclinical studies suggest interference with Aβ toxicity and aggregation; clinical relevance remains uncertain.
6 Synaptic plasticity / neurotransmission Cholinergic tone modulation (reported); synaptic resilience ↑ G Cognitive support Some evidence suggests improved synaptic function and neurotransmission in aging models.
7 Apoptosis suppression (neuronal survival) Pro-apoptotic signaling ↓ (reported) G Neuronal preservation Reduction of caspase activation and mitochondrial apoptotic signaling has been reported in neuronal injury models.
8 Clinical cognitive outcomes Modest cognitive benefit in mild-to-moderate dementia (mixed results) — Symptom-level effect Some randomized trials suggest small improvements in cognition or activities of daily living; others show limited effect. Benefit appears modest.
9 Safety constraint (antiplatelet effect) Bleeding risk ↑ in susceptible patients — Clinical risk management PAF antagonism and platelet aggregation inhibition require caution with anticoagulants and perioperative settings.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid receptor and mitochondrial interactions)
  • R: 30 min–3 hr (acute inflammatory and redox signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
SMAD2, SMAD family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
SMAD2 (SMAD family member 2) is a protein that plays a crucial role in the transforming growth factor-beta (TGF-β) signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and apoptosis.
In some cancers, SMAD2 functions as a tumor suppressor. TGF-β signaling can inhibit cell proliferation and promote apoptosis in normal and early-stage cancer cells. In this context, SMAD2 helps to mediate these effects, and its loss or mutation can contribute to tumor progression. Conversely, in advanced cancers, TGF-β signaling can promote tumor progression and metastasis. In these cases, SMAD2 may contribute to the epithelial-to-mesenchymal transition (EMT), a process that allows cancer cells to acquire migratory and invasive properties. This dual role can make targeting the TGF-β/SMAD2 pathway challenging in cancer therapy.
Scientific Papers found: Click to Expand⟱
1117- Gb,    Ginkgobiloba leaf extract mitigates cisplatin-induced chronic renal interstitial fibrosis by inhibiting the epithelial-mesenchymal transition of renal tubular epithelial cells mediated by the Smad3/TGF-β1 and Smad3/p38 MAPK pathways
- vitro+vivo, Kidney, HK-2
α-SMA↓, COL1↓, TGF-β↓, SMAD2↓, SMAD3↓, p‑SMAD2↓, p‑SMAD3↓, p38↓, p‑p38↓, Vim↓, TIMP1↓, CTGF↓, E-cadherin↑, MMP1:TIMP1↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

p38↓, 1,   p‑p38↓, 1,  

Migration ⓘ

COL1↓, 1,   CTGF↓, 1,   E-cadherin↑, 1,   MMP1:TIMP1↑, 1,   SMAD2↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   Vim↓, 1,   α-SMA↓, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: SMAD2, SMAD family member 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:89  Target#:283  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page